DAILIES® AquaComfort Plus® Multifocal (MF) - Comparative Assessment of Visual Performance
8. juni 2016 oppdatert av: Alcon Research
DAILIES® AquaComfort Plus® MF - Comparative Assessment of Visual Performance Using Objective Measurements
The purpose of this study is to evaluate the visual performance of DAILIES® Aqua Comfort Plus® (DACP) MF contact lens using new objective measurements.
Studieoversikt
Status
Fullført
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
In this 3-treatment, 3-period, 6-sequence crossover study, each subject received all 3 products in randomized order and used 1 product at a time for a duration of 5±1 days before switching to the next assigned product.
Studietype
Intervensjonell
Registrering (Faktiske)
24
Fase
- Ikke aktuelt
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
41 år til 65 år (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- History of soft contact lens wear (hydrogel or silicone hydrogel) in both eyes during the past 3 months and able to wear lenses at least 8 hours a day, 5 days a week
- Spectacle add between +1.50 and +2.50 diopters (D) (inclusive)
- Requiring lenses within the power range of both study contact lenses to be fitted
- Cylinder, if present, less or equal to 0.50D in both eyes at Visit 1
- Vision correctable to 20/30 (0.2 logMAR) or better in each eye at distance
- Acceptable fit with both study contact lenses
- Willing to wear lenses every day or at least for a minimum of 5 days per week 6 hours per day, every day if possible
- Other protocol-defined inclusion criteria may apply
Exclusion Criteria:
- Current multifocal contact lens wearer
- Current monovision wearer or failed attempt with monovision
- Ocular anterior segment infection, inflammation, abnormality, or active disease that would contraindicate contact lens wear
- Use of systemic or ocular medications which contact lens wear could be contraindicated as determined by the investigator
- Eye injury or surgery within 12 weeks immediately prior to enrollment in this trial
- Any moderate or severe ocular condition observed during the slitlamp examination at the enrollment visit
- History of herpetic keratitis, ocular surgery or irregular cornea
- Prior refractive surgery (e.g. LASIK, PRK, etc)
- Monocular (only 1 eye with functional vision) or fit with only 1 lens
- Habitually uncorrected anisometropia >2.00D
- Clinically significant anisocoria
- Participation in any clinical trial within 30 days of the enrollment visit
- Other protocol-defined exclusion criteria may apply
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Crossover-oppdrag
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: DACP MF
DACP MF worn first, followed by DACP and DACP MF (Low Add) as randomized.
Lenses worn for 5±1 days, 6 hours per day, in a daily wear daily disposable modality.
DACP MF will be worn bilaterally (in both eyes).
|
Multifocal contact lenses in Low, Medium, High Add
|
|
Aktiv komparator: DACP
DACP worn first, followed by DACP MF and DACP MF (Low Add), as randomized.
Lenses worn for 5±1 days, 6 hours per day, in a daily wear daily disposable modality.
DACP worn as monovision (distance correction in one eye and near correction in the other eye).
|
Multifocal contact lenses in Low, Medium, High Add
|
|
Aktiv komparator: DACP MF (Low Add)
DACP MF (Low Add) worn first, followed by DACP and DACP MF, as randomized.
Lenses worn for 5±1 days, 6 hours per day, in a daily wear daily disposable modality.
DACP MF (Low Add) worn bilaterally (in both eyes).
|
Multifocal contact lenses in Low, Medium, High Add
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Area for Each Region (Near and Intermediate) Under the Mean Defocus Curve (AUC) at High Luminance
Tidsramme: Day 5, each product
|
Visual acuity was measured with contact lenses in place using an Early Treatment Diabetic Retinopathy Study (ETDRS) high contrast logMAR chart under well-lit conditions.
Lenses of different spherical powers (+2.00 diopter to -5.00 diopter) were placed in front of the eyes to produce varying levels of defocus, and logMAR acuity at each defocus value was recorded.
The area under the defocus curve (AUC) was calculated via the trapezoidal rule for the entire study population by treatment using a 0.3 logMAR threshold for intermediate from -2.00 D (50cm) to -0.50 D (2m) and near from -4.00 D (25cm) to -2.00 D (50cm).
A higher value indicates a bigger area of focus.
This outcome measure was prespecified for monovision and DACP MF.
|
Day 5, each product
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Etterforskere
- Studieleder: Clinical Manager, EMEA, Alcon Research
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart
1. september 2014
Primær fullføring (Faktiske)
1. oktober 2014
Studiet fullført (Faktiske)
1. oktober 2014
Datoer for studieregistrering
Først innsendt
8. september 2014
Først innsendt som oppfylte QC-kriteriene
9. september 2014
Først lagt ut (Anslag)
10. september 2014
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
11. juli 2016
Siste oppdatering sendt inn som oppfylte QC-kriteriene
8. juni 2016
Sist bekreftet
1. juni 2016
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- CLT330-P001
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .